Parkinsonism & Related Disorders

Article	Citations
Cerebello-thalamofrontal dysconnectivity in paroxysmal kinesigenic dyskinesia: A resting-state fMRI study	107
Hemiatrophy-hemiparkinsonism and Poland syndrome: A causative or coincidental association?	104
Fear among patients with Parkinson's disease and repeated falls: Analysis of skin conductance responses during simulated accidents	68
Apomorphine sublingual film for “OFF” episodes in Parkinson’s disease: analysis of baseline factors	61
Leigh-like syndrome as a presentation of biallelic variants in DNAJC30 gene with predominant putamen degeneration and limb dystonia	59
Critical Appraisal of Economic Evaluation of Biomarkers Used for Screening of Dementia	58
A novel summary index derived from Kinect to evaluate the severity of postural abnormalities in patients with Parkinson’s Disease	53
White matter connectivity networks predict early dementia conversion in Parkinson’s disease	51
Early onset hemichorea-parkinsonism with POLG mutation without external ophthalmoplegia responsive to pallidal DBS	51
Examination of cognitive function in Parkinson's disease patients with chronic kidney disease	49
Chorea-Acanthocytosis: A Case Report	49
Association of Baseline Serum Urate Levels with Longitudinal General Cognition in Non-Demented Parkinson's Disease	49
“Pop-up” studies: Observational studies in Huntington disease conducted at annual family convention	46
Association and Spatiotemporal Progression Patterns of Dopamine Availability and Deep Gray Matter Volume in Parkinson’s Disease–related Cognitive Impairment	44
Role of linagliptin, a dipeptidyl peptidase-4 inhibitor against oxidative stress and neuronal damage in experimental diabetic aging brain of female rats of different age groups.	43
Targeting sedentary behavior decreases depressive symptoms and improves sleep in people with Parkinson’s Disease	41
β-Caryophyllene decreases neuroinflammation and exerts neuroprotection of dopaminergic neurons in a model of hemiparkinsonism through inhibition of the NLRP3 inflammasome	41
Fibrinogen exacerbates GCase ubiquitination via ATF5-induced TRIP12 activation in Parkinson's Disease	41
Association between serum lipid levels and dopamine loss in idiopathic rapid eye movement sleep behavior disorder	39
Objective sleep enhancement in Parkinson's disease: A sham-controlled trial of low-frequency repetitive transcranial magnetic stimulation over the right dorsolateral prefrontal cortex	38
Early-onset Parkinson's disease, regional and national burden, and its attributable risk factors in 204 countries and regions from 1990 to 2021: Results from the global burden of disease study 2021	36
Relation between Clinical and Electrophysiological Correlates of Peripheral Polyneuropathy and Oral Levodopa Treatment in People with Parkinson’s Disease	35
Integrity of Dopaminergic Terminals in the Caudate Nucleus Modulates Rest Tremor in Parkinson’s Disease	34
Digital devices and wearable technology for quantification of freezing of gait in adolescents with pediatric movement disorders attending school	32
Longitudinal brain changes in Parkinson's disease with severe olfactory deficit	32

Is rapid eye movement sleep behavior disorder a marker of Parkinson's disease severity?	32
Associations of cerebrospinal fluid monoamine metabolites with striatal dopamine transporter binding and 123I-meta-iodobenzylguanidine cardiac scintigraphy in Parkinson's disease: Multivariate analyse	31
Perry disease in an Argentine family due to the DCTN1 p.G67D variant	30
Effects of an intensive, multidisciplinary rehabilitative treatment in an outpatient setting on clinical outcomes in Parkinson’s Disease: preliminary results.	30
Leveraging Telehealth and Wearables for Parkinson’s Disease: Innovative Approaches to Enhance Personalized Care	29
Malignant Neuroleptic Syndrome in a Patient with Huntington's Disease	28
APOE carrier status and cognitive outcomes after STN-DBS surgery for Parkinson’s disease.	28
Mitochondrial and autophagic dysfunctions of skin fibroblasts derived from pantothenate kinase-associated neurodegeneration patients carrying PANK2 mutations and the rescuing effects of allantoin	28
Effect of ND0612 Continuous Infusion on Motor Performance and Experiences of Daily Living in Patients With Parkinson’s Disease	28
FindPD.DaT: Development of a Novel Artificial Intelligence-driven Tool for Diagnosis of Parkinson’s Disease using Dopamine Transporter Scans	27
Error-based biofeedback for gait training in Parkinson's disease	27
Establishing a framework for quality of inpatient care for Parkinson's disease: A study on inpatient medication administration	26
A case of probable Progressive Supranuclear Palsy Frontal type (PSP-F) presenting as psychosis	26
Dual Phase 18F-FP-CIT PET in presynaptic and trans-synaptic nigrostriatal dysfunction in Multiple System Atrophy	26
Bilateral Hemimasticatory spasm in a patient with hypereosinophilic syndrome	25
Neurocognition, Cerebellar Functions and Psychiatric Features in Spinocerebellar Ataxia Type 34	25
Postural abnormalities in Asian and Caucasian Parkinson's disease patients: A multicenter study	25
Perioperative quantification of MDS-UPDRS-III tremor measurements in patients with Parkinson’s Disease using accelerometry	25
A useful cognitive motor dual task paradigm in prodromal and manifest Huntington’s disease	24
Treatment of refractory post-hypoxic myoclonus and focal epilepsy with subthalamic nuclei deep brain stimulation	24
Magnetic resonance spectroscopy reveals evidence of brain oxidative stress in Tourette syndrome	23
Prevalence and clinical impact of alpha-synuclein pathology in idiopathic normal pressure hydrocephalus: Insights from RT-QuIC assay	23
Diet quality and prodromal Parkinson's disease probability in isolated REM sleep behavior disorder	23
The effects of stretching in Parkinson's disease: A systematic review of randomized controlled trials	23
Asymmetric Parkinsonism and Ataxia with autonomic dysfunction and RBD	23
Psychometric analysis of the short form UCLA Loneliness Scale (ULS-8) in people with Parkinson's disease	23
Are there morphological differences between Parkinson's disease-dementia and dementia with Lewy bodies?	22
Retinal microvascular impairment in Parkinson's disease with cognitive dysfunction	22
Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum	22
Preformed fibrils generated from mouse alpha-synuclein produce more inclusion pathology in rats than fibrils generated from rat alpha-synuclein	22
Diagnosis of vascular parkinsonism: A new tool for gait hypokinesia occurring in older persons	22
Exosomal miRNA as peripheral biomarkers in Parkinson's disease and progressive supranuclear palsy: A pilot study	22
Cognitive impairment in REM-sleep behaviour disorder and individuals at risk of Parkinson's disease	22
Evaluation of mild cognitive impairment in older patients with essential tremor	22
The diagnostic value of clinical neurophysiology in hyperkinetic movement disorders: A systematic review	21
The Elevated Risk of Dementia in Parkinson's Disease Patients Associated with Metabolic Syndrome	21
Gerstmann-Straussler-Scheinker disease: Lessons from two new Indian kindreds	21
Machine Learning Analysis of the Interaction Between miR-155 and LRRK2 Gene Variants in Parkinson's Disease Progression	20
Parkinson’s Disease with Hyposmia and Dysautonomia: Does It Represent a Distinct Subtype?	19
Association between global cognitive function and autonomic dysfunction in patients with de novo Parkinson’s disease	19
Unveiling the Complexity of Parkinson's Disease: Exploring Subtypes and Tracing its Five-Stage Natural Course	19
The role of neurotrophic factors in development Parkinson's disease dementia	19
Somnolence-Related Events Over Time During Valbenazine Treatment for Chorea Associated with Huntington’s Disease	19
Huntington Disease – Update on Recent Advances and a Look Toward the Future	19
Establishing exercise habits in patients with Parkinson's disease through an exercise group model	19
Clinical Evaluation of Parkinson's Disease Patients Admitted to the Movement Disorders Outpatient Clinic of Istanbul Taksim Training and Research Hospital, Turkey, 2023	19
Study of 17β estradiol with neuropeptide and amyloid beta fragment on neuronal and biochemical functions in naturally menopausal aging rats	18
Hereditary Spastic Paraparesis with SPG6 mutation: First case report from Malaysia	18
Efficacy of Once-Daily Valbenazine in Adults with Chorea Associated with Huntington’s Disease: Effect Size Over Time	18
Atypical antipsychotic use and mortality risk in Parkinson disease	18

The characteristic and prognostic role of blood inflammatory markers in patients with Huntington's disease from China	18
Proteomic profile of saliva in patients with Parkinson's disease after the practice of interval exercise	18
The psychological correlates of fatigue in Parkinson's disease: Contribution of maladaptive metacognitive beliefs	18
Alterations in electrochemical skin conductance as a marker of autonomic dysfunction in multiple system atrophy	18
Carrier Mediated Delivery System Bearing Dopamine for Effective Management of Parkinsonism	18
A late-onset neurological disorder: Is progression inevitable? Expert Commentary	18
From writer's cramp to blepharoclonus: An atypical journey with a novel KMT2B variant	18
Efficacy and safety of high doses of safinamide in advanced Parkinson disease	18
Dopaminergic dysfunctions instigated by Nano-formulation of Neonicotinoid pesticides in mice	17
Colony-Stimulating Factor-1 Receptor-Related Disorders in the Hispanic Population: A Report of six Families	17
Wearable sensors for assessing disease severity and progression in Progressive Supranuclear Palsy	17
On demand inhaled levodopa in Parkinson´s disease (pd) patients with device assisted therapies	17
A young man with progressive dysarthria, generalized slowness and memory loss	17
Protective Lifestyle Risk Factors Against Parkinson’s Disease In Sub-Saharan Africa: A Review On Current Evidence	17
The MemTrax memory test for detecting and assessing cognitive impairment in Parkinson's disease	17
Effect of Safinamide on Non-motor symptoms and QoL According to Sex, Age, Disease Duration and Levodopa Equivalent Daily Dose	17
The BEACON Study: LRRK2 inhibition by BIIB122/DNL151 in participants with Pathogenic LRRK2 Variants and Parkinson’s disease	17
Cystatin C as a Biomarker for the Development of Parkinson disease in Patients with Chronic Kidney Disease	17
Tardive dyskinesia versus tardive syndrome. What is in a name?	17
Brittle dyskinesias after bilateral STN DBS: dissociation of microlesioning effect on tremor versus on dyskinesias	16
Sex differences for cognitive decline in progressive supranuclear palsy	16
Atypical Presentation of Autosomal Recessive Cerebellar Ataxia Type I Mimicking Amyotrophic Lateral Sclerosis	16
Frequency settings of subthalamic nucleus DBS for Parkinson's disease: A systematic review and network meta-analysis	16
Commentary on “The use of hypoglycemic drugs in Parkinson's disease: An updated meta-analysis of randomized controlled trials”	16
¿It Is Any Difference Between Directional Vs Omnidirectional Lead For Treatment In Parkinson Disease?	16
Machine Learning-based World Health Organization Disability Assessment Schedule for persons with Parkinson's disease	16
Impact of inpatient mobility on outcomes in Parkinson's disease	16
Editorial Board	16
Editorial Board	16
Flexible vs. standard subthalamic stimulation in Parkinson disease: A double-blind proof-of-concept cross-over trial	16
Editorial Board	16
Dentate calcifications with palatal tremor and facial myorhythmia in adult-onset Cerebral X-linked Adrenoleukodystrophy	16
Levodopa, homocysteine and Parkinson's disease: What's the problem?	16
Editorial Board	15
Differences in progressive supranuclear palsy in patients of Asian ancestry?	15
Association of bilateral oophorectomy with incidence of Parkinson's disease: A systematic review and meta-analysis	15
Cognitive and neuropathological contributions to gait dysfunction in Parkinson's disease	15
Segmental dystonia as the prominent phenotype resulting from a MICU1 splice variant in a new Indian case	15
Functional movement disorders in dopa-responsive dystonia	15
The distinctive functional connectivity of the cholinergic nucleus basalis of Meynert in Parkinson’s disease across different cognitive status	15
A de novo GRIA3 variant with complex hyperkinetic movement disorder in a girl with developmental delay and self-limited epilepsy	15
Single-dose intranasal administration of α-syn PFFs induce lewy neurite-like pathology in olfactory bulbs	15
Personality assessment with Temperament and Character Inventory in Parkinson's disease	15
Predictors of multi-domain cognitive decline following DBS for treatment of Parkinson's disease	15
Effect of eight-week online cognitive training in Parkinson's disease: A double-blind, randomized, controlled trial	15
Long-term incobotulinumtoxinA treatment for chronic sialorrhea: efficacy and safety over 64 weeks	15
Expanding the phenotypic and genotypic spectrum of DYT-TUBB4A with seven patients from India	15
The impact of anti-inflammatory therapy on Parkinson's disease incidence: A retrospective cohort study	15
Genetic study of early-onset Parkinson's disease in the Malaysian population	15
Distractibility predicts favourable response of functional tremor to transcranial magnetic stimulation: An electrophysiological study	15
MRI index of glymphatic system mediates the influence of locus coeruleus on cognition in Parkinson's disease	15
Mitochondrial Membrane Protein-Associated Neurodegeneration (MPAN) Presenting With Parkinsonism Findings: A Case Report	14
Diagnostic value of α-synuclein seeding amplification assays in α-synucleinopathies: A systematic review and meta-analysis	14
Phenotypic manifestations of KIF5A Arg1007Lys mutation: A large kindred study	14
ERCC4 variants causing neurodegeneration with ataxia and chorea in three siblings in Lithuanian family	14
Genetic overlap between dystonia and other neurologic disorders: A study of 1,100 exomes	14
REM density in Parkinson’s disease: Effects of motor, cognitive, and autonomic function, and the impact of evening dopaminergic medication	14
MRgFUS of the nucleus ventralis intermedius in essential tremor modulates functional connectivity within the classical tremor network and beyond	14
Motor and non-motor responses of STN DBS in early onset PLA2G6 related Parkinsonism with compound heterozygous mutation from China	14
Augmented reality cueing for freezing of gait: Reviewing an emerging therapy	14
Neuropsychological studies in children with tic hyperkinesis	13
Subjective cognitive complaints are important in PD-MCI criteria: Associations with CSF markers and cognitive decline	13
Evaluating motor progression of juvenile-onset Huntington's Disease: An Enroll-HD analysis	13
Analysis of GIPC1 CGG repeat expansions in essential tremor	13
Interaction between caffeine intake and polymorphisms of PARK16 modifies Parkinson’s Disease risk	13
C19orf12 mutation carriers and their first-degree relatives require prospective clinical and genetic work-up	13
Post-COVID parkinsonism: A scoping review	13
Introducing Virtual Shared Medical Appointments as a Novel Treatment Platform for Functional Movement Disorders	13
Transcranial high-intensity Magnetic Resonance-guided focused ultrasound (tcMRgFUS) – safety and impacts on tremor severity and quality of life	13
Expanding the genotype-phenotype landscape of PDE10A-associated movement disorders	13
Identification of the needs of patients with Parkinson’s disease through a qualitative research process	13
Improvement of non-motor symptoms with NE3107 adjunctive to Carbidopa / Levodopa in patients with Parkinson`s disease: A Phase 2A, placebo-controlled study	13
Seronegative basal ganglia encephalitis mimicking dementia of Lewy body	13
The factors for choosing intesticular gel therapy	13
Longitudinal evaluation of patients with isolated head tremor	13
Empowering the management of early-onset Parkinson’s disease: The role of technology	13
Association between global cognitive function and autonomic dysfunction in patients with de novo Parkinson’s disease	13
The role of semispinalis capitis muscles in cervical dystonia with goose-neck posture	13
Sexual dysfunction in patients with focal dystonia	13
Cerebellar blood perfusion is a diagnostic, but not a prognostic, marker for parkinsonian-dominant type multiple system atrophy	12

Tremor is associated with familial clustering of dystonia	12
Late-onset parkinsonism in a patient with a novel frameshift THAP1 variant	12
Sweet as Parkinson's disease: Rethinking the impact of diabetes mellitus	12
Reliability of remote video ratings of the scale for assessment and rating of ataxia	12
Attainment of physiologic salivary flow rate with long-term incobotulinumtoxinA treatment for sialorrhea in Parkinson’s disease and other neurologic conditions	12
The use of hypoglycemic drugs in Parkinson's disease: An updated meta-analysis of randomized controlled trials	12
Spinocerebellar ataxia subtype 40: Report of a case and review of literature	12
Recent advances in non-Huntington's disease choreas	12
Dopaminergic connectivity reconfiguration in the dementia with Lewy bodies continuum	12
“A man with an arched back”: Expert commentary	12
The feasibility of using loss of “swallow tail sign” on 3T – susceptibility weighted MRI in diagnosis of Parkinson’s disease	12
The effects of once-daily opicapone 50 mg on the pharmacokinetics of levodopa administered as carbidopa/levodopa extended-release capsules: an open-label study	12
Thyroid disease in cervical dystonia	12
Response to levodopa in Parkinson's disease over time. A 4-year follow-up study	12
Grey matter correlates of dystonic soft signs in essential tremor	12
Convergence insufficiency and Parkinson's disease progression	12
Motor band sign in a Huntington disease phenocopy	12
Real-world effect of age on long-term effectiveness and safety of levodopa-carbidopa intestinal gel: post hoc analysis from the DUOGLOBE study	12
Cropland associated with risk of Parkinson's disease in the northern Great Plains	12
A case of treatable encephalopathy, developmental regression, and proximal tremor: Expert commentary	12
Comment on “Defining ‘OFF’ time in device-aided therapy criteria for Parkinson's disease: Gaps and opportunities”	12
Tongue strength in progressive supranuclear palsy	12
A structural perspective on the interaction between glucocerebrosidase and the positive allosteric modulator BIA 28-6156	11
TorsinA-interacting protein 2 (TOR1AIP2) variants in an autosomal dominant combined dystonia-hemichorea-hemiballismus syndrome in two families	11
The use of botulinum toxin A in the treatment of hand tremor	11
Sensor-based gait analysis in the premotor stage of LRRK2 G2019S-associated Parkinson's disease	11
Fecal tyrosine decarboxylase and motor response complications in Parkinson's disease	11
Magnetic Resonance Imaging Marker for the Conversion from Idiopathic Late-onset Cerebellar Ataxia to Multiple System Atrophy	11
Structural and functional brain abnormalities in idiopathic cervical dystonia: a multimodal meta-analysis	11
Accelerometric quantification of MDS-UPDRS bradykinesia measurements in PD patients: A pilot study	11
Right to the Point - A Writer’s Cramp Successful Treatment	11
Usage of modern technologies like VR therapy, physio therapy along with levodopa in Young-Onset Parkinson's disease patients	11
Profile of patients with advanced Parkinson’s disease treated with Levodopa–entacapone–carbidopa intestinal gel (LECIG)	11
Calcium channel blockers and Parkinson's disease: A systematic review and meta-analysis	11
Patients with progressive supranuclear palsy need to be seen sooner and more frequently	11
Challenges during prayer (namaz/salah) rituals in Muslim patients with Parkinson’s disease	11
WITHDRAWN	11
A challenging case of cerebellar ataxia associated with oro facial dominant chorea	11
Development of a screening AI model for Parkinson's disease using gait image sequences	11
Continuous subcutaneous levodopa/carbidopa infusion with ND0612 for Parkinson’s disease: Three-year data from the open-label BeyoND study	11
An atypical case of head tremor	11
Sex differences in the association between nonalcoholic fatty liver disease and Parkinson's disease	11
Increased blood-derived mitochondrial DNA copy number in African ancestry individuals with Parkinson's disease	11
Ethnoracial differences for caregiving burden in Parkinson’s disease	11
Opicapone Effect on Sleep Disorders in Fluctuating Parkinson’s Disease Patients: Findings from the OASIS Trial	11
Exposure factors and clinical characteristics associated with Parkinson's disease in GBA1 variant carriers: A Chinese GBA1-PD intrafamilial survey	11
Editorial Board	11
The iNPH Radscale May Better Predict Whether Ventriculoperitonal Shunting was Offered, Compared to Drain Trial Gait Variables	10
The influence of fatigue on motor imagery ability in people with Parkinson’s disease – preliminary study	10
Developing a Female-Specific Mouse Model for Parkinson’s Disease Using a High-Sensitivity Neural Network	10
Enhanced low beta activity in Park2-associated Parkinson’s disease	10
Preliminary verification of a Kinect-based system for evaluating postural abnormalities in patients with Parkinson’s disease	10
Development of osteomyelitis after COVID 19 in patients with vascular parkinsonism	10
Update: Protective and risk factors for Parkinson disease	10
Structural and functional connectomics of the olfactory system in Parkinson's disease: a systematic review	10
Real world evidence of efficacy ad safety of subcutaneus foslevodopa/foscarbidopa infusion in advanced Parkinson disease	10
Efficacy of Probiotics for treatment of constipation in Parkinson’s patients: a systematic review and meta-analysis	10
Plasma sphingolipids, dopaminergic degeneration and clinical progression in idiopathic Parkinson's disease	10
Backward leaning during gait: An underrecognized sign in Niemann-Pick type C	10
A relatively common hypomorphic variant in WARS2 causes monogenic disease	10
Utilizing technology-based outcome measures in the natural setting to answer intriguing clinical questions in Parkinson disease	10
Double blind, nonrandomized crossover study of active recharge biphasic deep brain stimulation for primary dystonia	10
Long-term safety of continuous levodopa/carbidopa infusion with ND0612: results from the ongoing BeyoND study	10
Clinical progression of vascular Parkinsonism in ischemic stroke patients with metabolic syndrome	10
Utility of clinical tests for asymmetry in Parkinson's disease and Atypical Parkinsonian disorders: the PARK-SYMM scale study.	10
Analysis of interleukin-6 levels in patients with Parkinson's disease by disease stage	10
Influence of Toxic Exposure on the Age of Onset of Parkinson's Disease: An Observational and Analytical Study.	10
Resting-state EEG predicts cognitive decline in a neuropathologically diagnosed longitudinal community autopsied cohort	10
A case of levodopa responsive parkinsonism due to methanol toxicity, an impact of COVID-19 crisis	10
Comparison of voice parameters, self-assessment of speech and sialorrhea levels in Parkinson's disease patients with and without swallowing problems	10
Leucine-rich repeat kinase2 (LRRK2) associated Parkinson's disease: less vulnerable during Covid-19 pandemic?	10
A novel GNAL pathogenic variant leading to generalized dystonia: Immediate and sustained response to globus pallidus internus deep brain stimulation	10
tDCS application for postural control in Parkinson's disease: Effects are associated with baseline characteristics	9
Association of subthalamic beta frequency sub-bands to symptom severity in patients with Parkinson's disease: A systematic review	9
Nigrostriatal dysfunction in RFC1-related disorder/CANVAS	9
A multidisciplinary telemedicine approach for managing frailty in Parkinson's disease. A longitudinal, case-control study	9
Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies	9
Magnetic Resonance–Guided focused ultrasound surgery for Parkinson's disease: A mini-review and comparison between deep brain stimulation	9
Assessment of Cerebral Cortical Atrophy Using Visual Rating Scale in Patients with Functional Movement Disorder	9
Demonstration of a Prototype Clinical Decision Support System for Diagnosing Parkinson’s Disease	9
High preoperative gait variability is a prognostic predictor of gait and balance in Parkinson disease patients with deep brain stimulation	9
Mild cognitive impairment among LRRK2 and GBA1 patients with Parkinson's disease	9
Diagnosis of Parkinson's disease from hand drawing utilizing hybrid models	9
A randomized clinical trial of candesartan for cognitive impairment in Parkinson's disease	9
Clinical correlations of cerebrospinal fluid biomarkers including neuron-glia 2 and neurofilament light chain in patients with multiple system atrophy	9
TMS-evoked potentials provide novel neurophysiological features of Tourette syndrome	9
MOBP gene risk variant is associated with higher cerebrospinal fluid levels of neurofilament light chain: a Barcelona PSP Registry study	9
Inter-muscular coherence in speed skaters with skater's cramp	9
A benign course of Parkinson's disease associated with different mutations in the glucocerebrosidase gene – A case series	9
Functional movement disorder comorbidity in Parkinson's disease: A multicenter descriptive study	9
Other clinical uses for apomorphine: Sedation and sleep disorders, withdrawal of oral dopaminergic medication, palliative care, restless legs syndrome, traumatic brain injury, sexual dysfunction	9
Multiple system atrophy like presentation with hot-cross bun sign in anti-IgLON5 disease	9
A case of treatable encephalopathy, developmental regression, and proximal tremor	9
Real-world local field potential recordings in patients with deep brain stimulation for Parkinson's disease	9
Parkinson's disease patients with absence of normal dipping status were more vulnerable to cognitive impairment from the early stages	9